CN112391462A - 一种子痫前期外周血浆中特异性miRNAs及其应用 - Google Patents
一种子痫前期外周血浆中特异性miRNAs及其应用 Download PDFInfo
- Publication number
- CN112391462A CN112391462A CN202011403940.7A CN202011403940A CN112391462A CN 112391462 A CN112391462 A CN 112391462A CN 202011403940 A CN202011403940 A CN 202011403940A CN 112391462 A CN112391462 A CN 112391462A
- Authority
- CN
- China
- Prior art keywords
- preeclampsia
- peripheral plasma
- specific mirnas
- application
- mirnas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 53
- 108091070501 miRNA Proteins 0.000 title claims abstract description 45
- 239000002679 microRNA Substances 0.000 title claims abstract description 44
- 230000002093 peripheral effect Effects 0.000 title claims abstract description 36
- 230000035935 pregnancy Effects 0.000 claims abstract description 14
- 108091024530 miR-146a stem-loop Proteins 0.000 claims description 5
- 108091040069 miR-146a-1 stem-loop Proteins 0.000 claims description 5
- 108091081537 miR-146a-2 stem-loop Proteins 0.000 claims description 5
- 108091032392 miR-146a-3 stem-loop Proteins 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000013399 early diagnosis Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了一种子痫前期外周血浆中特异性miRNAs及其应用，所述的miRNAs的核苷酸序列如SEQ ID NO.1所示。本发明所述的子痫前期外周血浆中特异性miRNAs在子痫前期患者及同孕周非子痫前期孕妇的外周血浆中均能够稳定表达且具有显著差异，该特异性miRNAs可应用于子痫前期的早期识别，并作为子痫前期患者及时终止妊娠的量化指标。
Description
技术领域
本发明属于分子生物学领域，尤其是涉及一种子痫前期外周血浆中特异性miRNAs及其应用。
背景技术
子痫前期(Pre-eclampsia，PE)作为女性妊娠期特有的疾病，发病率在0.2-2％之间，与自然流产、胎儿宫内生长受限、胎盘早剥及早产等密切相关，其起病隐匿，可快速进展并持续恶化，易发生急性肾衰、肝衰、脑出血、弥散性血管内凝血等严重并发症甚至危及母胎生命，严重危害母婴健康。目前，对于子痫前期孕妇的有效治疗措施是基于权衡母胎利弊之后的终止妊娠，这势必导致早产儿及新生儿并发症的增加。但由于对PE发病机制的了解有限，临床尚无可靠的预测手段及适时终止妊娠的生化指标。
miRNA是一类在真核生物体内广泛表达的非编码RNA分子，多由21-25个核苷酸组成，通过与靶基因转录产物mRNA的3′-UTR互补结合，抑制其翻译过程而调控靶基因的表达。目前人类成熟miRNAs的统计量已达2578个(miRBase20.0)，调控着近50％的蛋白编码基因。miRNA的表达具有组织特异性及时序性(即只在特定的组织和发育阶段表达)，这就意味着其在细胞生长和发育过程中起多种调节作用，包括：细胞增殖、凋亡、代谢、维持干细胞多能性及分化等。已有研究发现，miRNA可能参与调控胚胎的发育和选择、子宫内膜容受性的形成、母胎界面的血管重铸和免疫功能调节等，而上述的这些生物过程均与人妊娠的建立有密切关系，因此有理由相信miRNA在妊娠建立过程中具有重要作用。虽然其确切的作用机制有待阐明，但miRNA作为鉴别PE的候选分子在临床应用上具有广阔前景意见显露出来。
发明内容
有鉴于此，本发明旨在克服现有技术中的缺陷，提出一种子痫前期外周血浆中特异性miRNAs及其应用。
为达到上述目的，本发明的技术方案是这样实现的：
一种子痫前期外周血浆中特异性miRNAs，所述的miRNAs的核苷酸序列如SEQ IDNO.1所示。
进一步，所述的miRNAs为miR-146a-5p。
一种子痫前期外周血浆中特异性miRNAs的应用，所述的子痫前期外周血浆中特异性miRNAs在子痫前期的早期诊断中的应用。
进一步，所述的痫前期外周血浆中特异性miRNAs作为子痫前期早期诊断的分子标记物。
一种子痫前期外周血浆中特异性miRNAs的应用，所述的子痫前期外周血浆中特异性miRNAs在终止妊娠时限预测中的应用。
进一步，所述的痫前期外周血浆中特异性miRNAs作为子痫前期患者及时终止妊娠的量化指标。
一种子痫前期外周血浆中特异性miRNAs的应用，所述的子痫前期外周血浆中特异性miRNAs在制备诊断子痫前期试剂盒中的应用。
一种子痫前期外周血浆中特异性miRNAs的应用，所述的痫前期外周血浆中特异性miRNAs在制备治疗子痫前期药物中的应用。
一种试剂盒，所述的试剂盒含有miR-146a-5p或其检测试剂，和说明书，所述的说明书中注明所述的试剂盒用于判断子痫前期。
相对于现有技术，本发明具有以下优势：
本发明所述的子痫前期外周血浆中特异性miRNAs在子痫前期患者及同孕周非子痫前期孕妇的外周血浆中均能够稳定表达且具有显著差异，该特异性miRNAs可应用于子痫前期的早期识别，并作为子痫前期患者及时终止妊娠的量化指标。
附图说明
图1为本发明实施例所述的外周血浆中miR-146a-5p的表达量((p≦0.05)，COL组(n＝40例)：2.671±0.3098，PE组(n＝22例)：4.418±1.176)。
具体实施方式
除有定义外，以下实施例中所用的技术术语具有与本发明所属领域技术人员普遍理解的相同含义。以下实施例中所用的试验试剂，如无特殊说明，均为常规生化试剂；所述实验方法，如无特殊说明，均为常规方法。
下面结合实施例来详细说明本发明。
实施例1
选择于2019-2020期间在本院产科住院分娩的子痫前期患者(PE，n＝22)和同孕周分娩的非子痫前期孕妇(Control，CTR，n＝40)，均为因证剖宫产终止妊娠。
1、样品准备：外周血EDTA抗凝5ml，4℃，1000g转速离心5min，收集血浆于低温冰箱备用；
2、RNA抽提：取300μl血浆，4℃，1000g转速离心5min；取250μl上层血浆，先后加入TRI
及氯仿，离心取上清400μl加异丙醇及糖原，离心后弃上清；加75％乙醇洗涤沉淀并晾干，最后加入25μl预热至65℃的RNase-free水溶解RNA。
3、cDNA合成：将反转录引物等量混合成2μM的混合反转录引物；冰上解冻逆转录试剂盒，2000rpm转速下离心10-15s分至Ep管底；按照表1的预杂交体系配制混合液，彻底混匀后简短离心；按照表2的反转录反应体系配制混合液；将反转录反应中的Mix，加到预杂交的反应液中，充分混匀；25℃、孵育30min→42℃、孵育60min→95℃、孵育5min以终止RT反应；加入60μl RNase-free水至每支反应管中，上下反复吹打混匀，得到的cDNA即可用于后续实验。
表1预杂交体系
| 组成成分 | 使用量 |
| RNA* | 2.00μl |
| dNTPs(10μM) | 0.75μl |
| RT Primer Mix(2μM) | 0.75μl |
| RNase-free water | 1.50μl |
| 总体积 | 5.00μl |
表2反转录反应体系
4、实时定量PCR：
根据表3的内容进行反应液准备，在PCR板或八连管底部分别加入待检测上述稀释好的cDNA样本2μl，加8ul反应混合液到对应的每个孔中，根据表4实时定量PCR程序设置完后，将PCR Array置于实时定量PCR仪进行PCR反应。
表3反应液体系
| 组成成分 | 体积 |
| 2x master mix | 640μl |
| F(10μM) | 32μl |
| R(10μM) | 32μl |
| P(1μM) | 128μl |
| 已稀释的cDNA | / |
| ddH2O | 192μl |
| 总体积 | 1300μl |
表4 PCR程序设置
| 步骤 | 设置 |
| 聚合酶激活/变性 | 95℃，10分钟 |
| 扩增5个循环 | 95℃，10秒 |
| 58℃，20秒(U6引物用60℃) | |
| 72℃，30秒 | |
| 扩增45个循环 | 90℃，10秒 |
| 60℃，1分钟 | |
| 收集荧光 | |
| 溶解曲线分析** |
5、数据分析：采用ΔΔCt方法进行数据分析。
6、引物序列如表5所示。
表5引物序列
以上所述仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
序列表
<110> 天津医科大学第二医院
<120> 一种子痫前期外周血浆中特异性miRNAs及其应用
<130> 2020.12.04
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 22
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 1
ugagaacuga auuccauggg uu 22
Claims (9)
1.一种子痫前期外周血浆中特异性miRNAs，其特征在于：所述的miRNAs的核苷酸序列如SEQ ID NO.1所示。
2.根据权利要求1所述的子痫前期外周血浆中特异性miRNAs的应用，其特征在于：所述的miRNAs为miR-146a-5p。
3.一种子痫前期外周血浆中特异性miRNAs的应用，其特征在于：所述的子痫前期外周血浆中特异性miRNAs在子痫前期的早期诊断中的应用。
4.根据权利要求3所述的子痫前期外周血浆中特异性miRNAs的应用，其特征在于：所述的痫前期外周血浆中特异性miRNAs作为子痫前期早期诊断的分子标记物。
5.一种子痫前期外周血浆中特异性miRNAs的应用，其特征在于：所述的子痫前期外周血浆中特异性miRNAs在终止妊娠时限预测中的应用。
6.根据权利要求5所述的子痫前期外周血浆中特异性miRNAs的应用，其特征在于：所述的痫前期外周血浆中特异性miRNAs作为子痫前期患者及时终止妊娠的量化指标。
7.一种子痫前期外周血浆中特异性miRNAs的应用，其特征在于：所述的子痫前期外周血浆中特异性miRNAs在制备诊断子痫前期试剂盒中的应用。
8.一种子痫前期外周血浆中特异性miRNAs的应用，其特征在于：所述的痫前期外周血浆中特异性miRNAs在制备治疗子痫前期药物中的应用。
9.一种试剂盒，其特征在于：所述的试剂盒含有miR-146a-5p或其检测试剂，和说明书，所述的说明书中注明所述的试剂盒用于判断子痫前期。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011403940.7A CN112391462A (zh) | 2020-12-04 | 2020-12-04 | 一种子痫前期外周血浆中特异性miRNAs及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011403940.7A CN112391462A (zh) | 2020-12-04 | 2020-12-04 | 一种子痫前期外周血浆中特异性miRNAs及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112391462A true CN112391462A (zh) | 2021-02-23 |
Family
ID=74604277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011403940.7A Pending CN112391462A (zh) | 2020-12-04 | 2020-12-04 | 一种子痫前期外周血浆中特异性miRNAs及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112391462A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104232637A (zh) * | 2014-04-18 | 2014-12-24 | 首都医科大学附属北京佑安医院 | 肝硬化microRNA分子标志物及其用途 |
| CN107400728A (zh) * | 2017-09-21 | 2017-11-28 | 西安医学院 | miR‑155作为分子标记物在诊断子痫前期中的应用 |
| WO2020088704A1 (en) * | 2018-10-31 | 2020-05-07 | Univerzita Karlova, 3.Lekarska Fakulta | Postpartum epigenetic profile of cardiovascular micrornas in women exposed to pregnancy-related complications |
-
2020
- 2020-12-04 CN CN202011403940.7A patent/CN112391462A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104232637A (zh) * | 2014-04-18 | 2014-12-24 | 首都医科大学附属北京佑安医院 | 肝硬化microRNA分子标志物及其用途 |
| CN107400728A (zh) * | 2017-09-21 | 2017-11-28 | 西安医学院 | miR‑155作为分子标记物在诊断子痫前期中的应用 |
| WO2020088704A1 (en) * | 2018-10-31 | 2020-05-07 | Univerzita Karlova, 3.Lekarska Fakulta | Postpartum epigenetic profile of cardiovascular micrornas in women exposed to pregnancy-related complications |
Non-Patent Citations (3)
| Title |
|---|
| ILONA HROMADNIKOVA等: "Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripheral blood", 《THROMB RES》 * |
| 陈芳荣等: "miR-146a-5p通过调控TRAF6表达影响滋养细胞生物学行为", 《华中科技大学学报(医学版)》 * |
| 陈芳荣等: "长链非编码RNA MALAT1与微小核糖核酸-146a相互作用对子痫前期滋养细胞功能的影响", 《海南医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10731218B2 (en) | Methods employing circulating DNA and miRNA as biomarkers for female infertility | |
| Hu et al. | Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia | |
| Hromadnikova et al. | Absolute and relative quantification of placenta-specific microRNAs in maternal circulation with placental insufficiency–related complications | |
| Yang et al. | Differentially expressed plasma microRNAs in premature ovarian failure patients and the potential regulatory function of mir-23a in granulosa cell apoptosis | |
| Karakaya et al. | Poor ovarian response in women undergoing in vitro fertilization is associated with altered microRNA expression in cumulus cells | |
| JP2011510623A (ja) | 妊娠の合併症を診断するための方法及び組成物 | |
| JP2009535050A (ja) | 出生前診断及びモニタリングのための新規の胎児マーカー | |
| US20140296099A1 (en) | Use of MicroRNA for Assessing Embryos Grown in Vitro and Improving Culture Media | |
| US20200270690A1 (en) | Serum/plasma LncRNA marker composition associated with auxiliary diagnosis of intrahepatic cholestasis of pregnancy and application thereof | |
| CN113249458B (zh) | 一种预测胎盘源性疾病的评估和预测的方法和试剂盒 | |
| CN111455044B (zh) | 一种用于母羊早期妊娠诊断的外泌体miRNA标志物及其应用 | |
| RU2334233C1 (ru) | Способ прогнозирования преждевременных родов при урогенитальной инфекции | |
| CN112391462A (zh) | 一种子痫前期外周血浆中特异性miRNAs及其应用 | |
| CN112852946A (zh) | 一种诊断生物标志物及其应用 | |
| Veraguas et al. | In vitro and in vivo development of domestic cat embryos generated by in vitro fertilization after eCG priming and oocyte in vitro maturation | |
| CN116004849A (zh) | 一种用于母猪早期妊娠诊断的外泌体miRNA标志物及其应用 | |
| Gasca et al. | Total fertilization failure and molecular abnormalities in metaphase II oocytes | |
| Monfared et al. | Determination and comparison miR 5a in the serum between women with GDM, non-pregnant type diabetes, healthy pregnant and control group | |
| Go et al. | C21ORF105, A chromosome 21‐encoded mRNA, is not a discriminative marker gene for prediction of Down syndrome in maternal plasma | |
| WO2012061898A1 (en) | Method of assessing oocytes | |
| WO2016142688A1 (en) | Method for predicting cervical shortening and preterm birth | |
| CN112111571A (zh) | 一种评估冠心病预后的分子标志物miR-223及其应用 | |
| RU2771205C1 (ru) | Количественная оценка соотношения hsa-miR-30c-5/VIM, hsa-miR-28-3p/VIM, hsa-miR-1-3p/ANXA2, hsa-miR-30c-5p/FBN1, hsa-miR-15b-5p/MYL6 tr.v.1, hsa-miR-15b-5p/MYL6 tr.v.2, hsa-miR-185-3p/FLNA, hsa-miR-1-3p/YWHAZ, hsa-miR-30c-5p/YWHAZ и hsa-miR-654-3p/FGA в плацентарной площадке женщин в день родоразрешения на сроке более 34 недель гестации как способ дифференциальной диагностики синдрома задержки развития плода, преэклампсии и синдрома маловесного к сроку гестации плода | |
| CN101792802A (zh) | SRY特异性TaqMan探针引物对与实时荧光SRY基因检测试剂盒 | |
| CN114703271B (zh) | 一种调控ICP过程中胎盘滋养细胞凋亡与增殖的LncRNA及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210223 |